BIOAGE LABS, INC. Earnings Per Share (Basic)
BIOAGE LABS, INC. (BIOA) reported Earnings Per Share (Basic) of -$0.58 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- BIOAGE LABS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.58.
- BIOAGE LABS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.52.
- BIOAGE LABS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.72.
- BIOAGE LABS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.56.
- BIOAGE LABS, INC. earnings per share, basic for fiscal 2025 was -$2.24.
- BIOAGE LABS, INC. earnings per share, basic for fiscal 2024 was -$6.63.
- BIOAGE LABS, INC. earnings per share, basic for fiscal 2023 was -$38.17.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.58 10-Q · filed 2026-08-05 | -$1.11 10-Q · filed 2026-08-05 | -$1.80 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.37 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.52 10-Q · filed 2026-05-08 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.39 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-03-24 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-03-24 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.24 10-K · filed 2026-03-24 |
| 2025-09-30 | -$0.56 10-Q · filed 2025-11-06 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.52 10-Q · filed 2025-11-06 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.60 10-Q · filed 2026-08-05 | -$0.96 10-Q · filed 2026-08-05 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.84 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.36 10-Q · filed 2026-05-08 | -$0.95 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.29 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.69 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2024-12-31 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-03-24 | -$2.25 derived: net income ÷ weighted average shares · filed 2026-03-24 | -$4.23 derived: net income ÷ weighted average shares · filed 2026-03-24 | -$6.63 10-K · filed 2026-03-24 |
| 2024-09-30 | -$6.70 10-Q · filed 2025-11-06 | -$14.21 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$21.76 10-Q · filed 2025-11-06 | -$33.18 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | -$7.94 10-Q · filed 2025-08-06 | -$15.70 10-Q · filed 2025-08-06 | -$28.19 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$36.94 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-03-31 | -$7.76 10-Q · filed 2025-05-06 | -$20.29 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$29.03 derived: net income ÷ weighted average shares · filed 2025-11-06 | |
| 2023-12-31 | -$12.53 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$21.27 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$38.17 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$8.74 10-Q · filed 2024-11-07 | -$25.64 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |